CPLX2 is a novel tumor suppressor and improves the prognosis in glioma
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature..
BACKGROUND: Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation.
METHODS: The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed.
RESULTS: The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways.
CONCLUSIONS: Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:167 |
|---|---|
| Enthalten in: |
Journal of neuro-oncology - 167(2024), 1 vom: 08. März, Seite 63-74 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Chen, Yuanbing [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adaptor Proteins, Vesicular Transport |
|---|
| Anmerkungen: |
Date Completed 29.03.2024 Date Revised 09.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1007/s11060-023-04548-4 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369170261 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369170261 | ||
| 003 | DE-627 | ||
| 005 | 20240409232527.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s11060-023-04548-4 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1370.xml |
| 035 | |a (DE-627)NLM369170261 | ||
| 035 | |a (NLM)38427133 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Chen, Yuanbing |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a CPLX2 is a novel tumor suppressor and improves the prognosis in glioma |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.03.2024 | ||
| 500 | |a Date Revised 09.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. | ||
| 520 | |a BACKGROUND: Glioma is a type of malignant cancer that affect the central nervous system. New predictive biomarkers have been investigated in recent years, but the clinical prognosis for glioma remains poor. The function of CPLX2 in glioma and the probable molecular mechanism of tumor suppression were the focus of this investigation | ||
| 520 | |a METHODS: The glioma transcriptome profile was downloaded from The Cancer Genome Atlas (TCGA) and Chinese Glioma Genome Atlas (CGGA) databases for analysis of CPLX2 expression in glioma. RT-qPCR was performed to detect the expression of CPLX2 in 68 glioma subjects who have been followed up. Kaplan-Meier survival analyses were conducted to assess the effect of CPLX2 on the prognosis of glioma patients. The knockdown and overexpressed cell lines of CPLX2 were constructed to investigate the impact of CPLX2 on glioma. The cell growth, colony formation, and tumor formation in xenograft were performed | ||
| 520 | |a RESULTS: The expression of CPLX2 was downregulated in glioma and was negatively correlated with the grade of glioma. The higher expression of CPLX2 predicted a longer survival, as indicated by the analysis of Kaplan-Meier survival curves. Overexpressed CPLX2 impaired tumorigenesis in glioma progression both in vivo and in vitro. Knocking down CPLX2 promoted the proliferation of glioma cells. The analysis of GSEA and co-expression analysis revealed that CPLX2 may affect the malignancy of glioma by regulating the hypoxia and inflammation pathways | ||
| 520 | |a CONCLUSIONS: Our data indicated that CPLX2 functions as a tumor suppressor and could be used as a potential prognostic marker in glioma | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a CPLX2 | |
| 650 | 4 | |a Glioma | |
| 650 | 4 | |a Hypoxia | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Tumor suppressor gene | |
| 650 | 7 | |a complexin II |2 NLM | |
| 650 | 7 | |a Nerve Tissue Proteins |2 NLM | |
| 650 | 7 | |a Adaptor Proteins, Vesicular Transport |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Proteins |2 NLM | |
| 700 | 1 | |a Ning, Jieling |e verfasserin |4 aut | |
| 700 | 1 | |a Shu, Long |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, Lingzhi |e verfasserin |4 aut | |
| 700 | 1 | |a Yan, Bokang |e verfasserin |4 aut | |
| 700 | 1 | |a Wang, Zuli |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Junhong |e verfasserin |4 aut | |
| 700 | 1 | |a Zhou, Xiaokun |e verfasserin |4 aut | |
| 700 | 1 | |a Tao, Yongguang |e verfasserin |4 aut | |
| 700 | 1 | |a Xia, Xuewei |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Jun |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of neuro-oncology |d 1993 |g 167(2024), 1 vom: 08. März, Seite 63-74 |w (DE-627)NLM012591793 |x 1573-7373 |7 nnns |
| 773 | 1 | 8 | |g volume:167 |g year:2024 |g number:1 |g day:08 |g month:03 |g pages:63-74 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1007/s11060-023-04548-4 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 167 |j 2024 |e 1 |b 08 |c 03 |h 63-74 | ||